Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. Low Float Hunters Message Board

CBIS News -- Cannabis Science Launches a Global Co

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 1193
(Total Views: 275)
Posted On: 08/23/2017 9:44:35 AM
Avatar
Posted By: stockseekerok
CBIS News -- Cannabis Science Launches a Global Consortium and Announces Updates on Its Drug Development Initiatives and Research Collaborations
[Marketwired]
MarketwiredAugust 23, 2017

IRVINE, CA--(Marketwired - Aug 23, 2017) - Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the launch of the Cannabis Science Global Consortium and to provide updates on the Company's drug development initiatives and research collaborations.

The Cannabis Science Global Consortium provides the Company with a framework to cooperate and collaborate with stakeholders worldwide. "The objective of our consortium is to harness the collective expertise of our global partners to investigate the use of Cannabinoids for the treatment of a variety of indications, including cancers, neurological conditions, pain management, the treatment of HIV and AIDS, and epilepsy," stated Mr. Raymond C. Dabney, President, Chief Executive Officer, Co-founder, and Director of Cannabis Science. "The Cannabis Science Global Consortium will link universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside." The Cannabis Science Global Consortium will also enable the Company to more strategically coordinate its initiatives, including those focused on education, job creation, and skills training.

Cannabis Science is aggressively expanding the Company's network of research centers. Negotiations are ongoing with several academic institutions in the United States and internationally to establish new, collaborative research agreements. These contracts will focus on several indications, and are expected to expand the research funded and directed by the Company. In addition, Cannabis Science will develop multi-center, clinical trial networks with cannabinoid drug development.

Cannabis Science currently has several research programs underway that have produced initial results that are critical in the Company's early phase cancer drug development plan. "These initial results are better than expected and are helping Cannabis Science refine our drug development program," stated Dr. Allen Herman, Chief Medical Officer of Cannabis Science. "Based on our progress to date, we expect to conclude pre-clinical work on a few cannabinoids over the next several months, and begin clinical trials in 2018. This timeline is consistent with the Company's overall development strategy."

There are three primary elements in Cannabis Science's drug development program: (1) Defining the effectiveness and specificity of cannabinoids being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in our randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions.

"These initial experiments follow the outlines of the proposed research described in the 2016 National Academies of Sciences, Engineering, and Medicine Report on the use of Cannabinoids in medical care," said Dr. Herman "This work defines the vital early steps in our drug development program that will bring new pharmaceuticals to the treatment of many diseases."


(0)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us